GALNT14-rs9679162 Genotypes Predict Post-immunotherapy Side Effect and Survival in Patients with Hepatitis B Virus-related Hepatocellular Carcinoma
Po-Ting Lin, Wei Teng, Wei-Ting Chen, Yu-De Chu, Chung-Wei Su, Yi-Chung Hsieh, Chen-Chun Lin, Yung-Chang Lin, Chun-Yen Lin, Chau-Ting Yeh, Shi-Ming Lin · 2026
Read GALNT14-rs9679162 Genotypes Predict Post-immunotherapy Side Effect and Survival in Patients with Hepatitis B Virus-related Hepatocellular Carcinoma by Po-Ting Lin, Wei Teng, Wei-Ting Chen, Yu-De Chu, Chung-Wei Su, Yi-Chung Hsieh, Chen-Chun Lin, Yung-Chang Lin, Chun-Yen Lin, Chau-Ting Yeh, Shi-Ming Lin (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13280630.txt.
Description
Po-Ting Lin and colleagues published a 2026 study on liver cancer tied to hepatitis B, a virus that harms the liver. The team asked whether small gene differences could predict how patients fare on immune therapy. Their chart review covered ninety-six patients treated between 2020 and 2023. All got two immune drugs given as standard care.
One gene form stood out. Patients who carried it went close to twenty months before their cancer grew again. They also had a lower chance of a sharp rise in a liver enzyme, a sign of liver strain. Four other gene variants showed no link. The authors say a simple gene test might help doctors plan care for these patients.
Catalog record
| CREATOR | Po-Ting Lin, Wei Teng, Wei-Ting Chen, Yu-De Chu, Chung-Wei Su, Yi-Chung Hsieh, Chen-Chun Lin, Yung-Chang Lin, Chun-Yen Lin, Chau-Ting Yeh, Shi-Ming Lin |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 24506 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |